Mass Tort Inventory Finance vs. Single-Plaintiff Advance

Mass tort inventory finance suits a plaintiff firm managing a large book of claims within an MDL or state consolidation — client acquisition, medical record retrieval, expert development, and years of carrying costs across hundreds or thousands of claimants — and that needs capital sized to the whole inventory rather than any single claim. It is particularly relevant to firms whose intake volume has outgrown what their own working capital can sustain.

A single-plaintiff advance suits one individual plaintiff within a mass tort who needs personal funds — living expenses, medical bills, or other costs — while their specific claim moves through the litigation, independent of how the firm as a whole is financing its broader inventory. It is a consumer-facing product distinct from the firm-level facility their attorney may separately hold.

The funder evaluates the firm's docket composition, the strength of the underlying science, the procedural posture of the MDL or consolidation, and the defendant's settlement history, then extends capital against the aggregate expected value of the inventory, with the facility structured to accommodate ongoing intake and resolution as the litigation progresses toward bellwether trials or a global settlement. The facility is typically revalued as bellwether outcomes and general causation rulings clarify the litigation's likely trajectory.

The funder evaluates that specific plaintiff's claim — exposure history, diagnosis, and expected participation in any global settlement grid — and advances a portion of the plaintiff's anticipated individual recovery, repaid from that plaintiff's own settlement proceeds and entirely independent of how the broader inventory performs. Underwriting for an individual advance is necessarily narrower than a firm-level inventory review, since only one claimant's specific facts are at issue.

Pricing reflects the aggregate risk of the inventory, diversified across many individual claims with a shared legal and scientific theory, which generally supports more favorable terms per dollar deployed than financing plaintiffs individually, since a handful of weaker claims within the inventory does not sink the whole facility. This diversification benefit is the central economic reason firms prefer inventory-level financing once their docket reaches sufficient scale.

Pricing reflects that specific plaintiff's claim in isolation, priced against the individual's likely placement within the settlement grid or points system once one exists, without the benefit of the inventory-wide diversification a firm-level facility provides. Because no grid may yet exist early in the litigation, pricing at that stage relies more heavily on general exposure and diagnosis criteria than on a specific expected payout figure.

Risk is distributed across the inventory's many claimants, so weaker individual claims or unfavorable bellwether results affect the whole facility's value but do not depend entirely on any single plaintiff's outcome, consistent with how mass tort settlements are typically negotiated and paid on an aggregate basis. A funder's exposure therefore tracks the inventory's overall trajectory rather than any one claimant's individual case file.

Risk is concentrated in that one plaintiff's claim and its ultimate placement in any settlement allocation, so a weaker exposure history or diagnosis for that specific individual affects only their own advance, not the firm's broader inventory financing. The plaintiff's advance remains non-recourse regardless of how the broader litigation or the firm's inventory facility ultimately performs.

Inventory finance wins when a firm needs capital to build and carry a mass tort docket at scale, ahead of the years typically required to reach bellwether trials or a global settlement, and wants a facility that grows with ongoing client intake.

A single-plaintiff advance wins when an individual claimant within a mass tort needs personal funds now, regardless of how or whether their firm has separately financed the broader inventory the claim sits within.